Organisation paid for research Program year 2025 Source: CMS Open Payments

Albuquerque Clinical Trials

Neither a doctor nor a teaching hospital

Research payments

$1,661,721

582 payments

Through program year 2025, Albuquerque Clinical Trials is reported as receiving $1,661,721 in research payments, across 582 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $158,506 25
2024 Research $90,556 4
2023 Research $40,857 22
2022 Research $73,644 12
2021 Research $173,443 36
2020 Research $558,166 194
2019 Research $566,549 289

Breakdown

Who paid Research payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $833,229 407 payments
  2. H. Lundbeck A S $281,224 45 payments
  3. Novartis Pharmaceuticals Corporation $143,342 6 payments
  4. GlaxoSmithKline, LLC. $126,175 21 payments
  5. Moderna TX, Inc. $72,882 21 payments
  6. AstraZeneca Pharmaceuticals LP $72,528 6 payments
  7. Mitsubishi Tanabe Pharma Development America, Inc. $43,024 4 payments
  8. C. R. Bard, Inc. & Subsidiaries $33,570 1 payment
  9. Allergan Inc. $22,717 16 payments
  10. Teva Pharmaceuticals USA, Inc. $19,450 15 payments
Studies the money was for Research payments · program years 2019–2025
  1. Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age $537,582 113 payments
  2. A Parallel Group, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Subjects Experiencing An Acute Attack of Migraine $145,078 31 payments
  3. Hps-4/Timi 65/Orion-4: A Double-Blind Randomized Placebo-Controlled Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Atherosclerotic Cardiovascular Disease $143,342 6 payments
  4. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-MonthStudy to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with ChronicCough PN030 $139,693 46 payments
  5. Evaluate Efficacy & Safety of Eptinezumab Administered Intravenously in Subjects Experiencing Acute Attack of Migraine (RELIEF) $117,052 3 payments
  6. A Randomized, Adaptive, Double-Blind, Placebo-Controlled, Parallel-Arm $110,661 13 payments
  7. A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of MT-2990 in Women with Endometriosis Experiencing Endometrial Related Pain $43,024 4 payments
  8. a phase third,randomised,double blind,placebo controlled,eventdriven study to evaluate the effect of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on the risk of incident heart failure and cardiovascular death in participants with increased risk of reveloping heart failure $42,193 1 payment
  9. A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age $39,769 10 payments
  10. A Phase 3b Randomized Double-blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Gefapixant in Women with Chronic Cough and Stress Urinary Incontinence $39,685 5 payments
What the money was spent on Research payments · program years 2019–2025
  1. Patient care $417 12 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record